Vivimed Labs launches Covid-19 drug Favulous in India

TAGS

Vivimed Labs has launched Favulous, its generic version of drug Tablet 200 mg and 400 mg in .

The launch follows the approval secured by the Hyderabad-based specialty chemicals and pharma company secured approval from the Indian Director General of Health Services (DGHS) for manufacturing and marketing Favipiravir.

Vivimed Labs said that it will closely work with the various governments and medical community in India for ensuring the availability of Favulous.

See also  Kirloskar Brothers Q3 FY23 profit after tax surges by 308% to Rs 89cr

Favipiravir is an oral anti-viral treatment, which has approvals in various countries for the potential treatment of Covid-19 in patients having mild to moderate disease.

Vivimed Labs launches Covid-19 drug Favulous in India

Vivimed Labs launches Covid-19 drug Favulous in India. Photo courtesy of Vivimed Labs Limited

– CEO of Vivimed Labs said: “With huge spike in Covid19 cases being reported daily in India, there is an urgent need to provide more treatment options to healthcare professionals.

See also  GACL, NTPC to partner on renewable energy and green chemicals

“We are launching “Favulous” at a competitive price to make the drug accessible to more and more patients thereby ensuring good health and reducing their financial burden. This is in line with Vivimed’s commitment to be at forefront in India’s fight against Covid-19.”


Discover more from Business-News-Today.com

Subscribe to get the latest posts sent to your email.

CATEGORIES
TAGS
Share This